Chapter 9 HIV Induced AIDS and Related Cancers. Chronic Immune Activation and Future Therapeutic Strategies

Advances in Cancer Research

Volumn 101, Issue , 2008, Pages 349-395

  Cadogan, Martin ^a   Dalgleish, Angus G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HLA A ANTIGEN; HLA B ANTIGEN; HLA B27 ANTIGEN; HLA B57 ANTIGEN; HLA B8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HLA ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNITY; DISEASE PREDISPOSITION; GRAFT VERSUS HOST REACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; KAPOSI SARCOMA; LYMPHOMA; NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS INFECTION; VIRUS LOAD; AIDS RELATED COMPLEX; ALLELE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DISEASE COURSE; IMMUNE SYSTEM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; TREATMENT OUTCOME; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALLELES; AMINO ACID SEQUENCE; ANIMALS; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; HIV INFECTIONS; HLA ANTIGENS; HUMANS; IMMUNE SYSTEM; MOLECULAR SEQUENCE DATA; NEOPLASMS; SEQUENCE HOMOLOGY, AMINO ACID; TREATMENT OUTCOME;

EID: 56849106137     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(08)00409-0     Document Type: Review

References (345)

1. Aasa-Chapman M.M., Hayman A., Newton P., Cornforth D., Williams I., Borrow P., Balfe P., and McKnight A. Development of the antibody response in acute HIV-1 infection. AIDS 18 (2004) 371-381
2. Acha-Orbea H., and Palmer E. Mls-A retrovirus exploits the immune system. Immunol. Today 12 (1991) 356-361
3. Al Jabri A.A. HLA and in vitro susceptibility to HIV infection. Mol. Immunol. 38 (2001) 959-967
4. Al Jabri A.A., McCloskey D., Affawee M., Bottazzo F.G., Sachs J., and Oxford J.S. In vitro correlation between human leukocyte antigen classes I and II phenotype and HIV infectivity of activated peripheral mononuclear cell cultures. AIDS 12 (1998) 217-218
5. Allen T.M., Yu X.G., Kalife E.T., Reyor L.L., Lichterfeld M., John M., Cheng M., Allgaier R.L., Mui S., Frahm N., Alter G., Brown N.V., et al. De novo generation of escape variant-specific CD8+ T cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J. Virol. 79 (2005) 12952-12960
6. Anderson D.J., and Yunis E.J. "Trojan Horse" leukocytes in AIDS. N. Engl. J. Med. 309 (1983) 964-965
7. Andrieu J.M., Lu W., and Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus 1-seropositive patients treated with prednisolone for 1 year. J. Infect. Dis. 171 (1995) 523-530
8. Arthur L.O., Bess J.W., Sowder R.C., Benveniste R.E., Mann D.L., Chermann J.C., and Henderson L.E. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science 258 (1992) 1935-1938
9. Ascher M.S., and Sheppard H.W. AIDS as immune system activation: A model for pathogenesis. Clin. Exp. Immunol. 73 (1988) 165-167
10. Atassi H., and Atassi M.Z. HIV envelope protein is recognized as an alloantigen by human DR-specific alloreactive T cells. Hum. Immunol. 34 (1992) 31-38
11. Atwood W.J., Tornatore C.S., Traub R., Conant K., Drew P.D., and Major E.O. Stimulation of HIV type 1 gene expression and induction of NF-κB (p50/p65)-binding activity in tumour necrosis factor α-treated human fetal glial cells. AIDS Res. Hum. Retroviruses 10 (1994) 1207-1211
12. Badley A.D., Dockrell D.H., Algeciras A., Ziesmer S., Landay A., Lederman M.M., Connick E., Kessler H., Kuritzkes D., Lynch D.H., Roche P., Yagita H., et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J. Clin. Invest. 102 (1998) 79-87
13. Badley A.D., Parato K., Cameron D.W., Kravcik S., Phenix B.N., Ashby D., Kumar A., Lynch D.H., Tschopp J., and Angel J.B. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ. 6 (1999) 420-432
14. Baldari C.T., Milia E., Di Somma M., Baldoni F., Valitutti S., and Telford J.L. Distinct signalling properties identify functionally different CD4 epitopes. Eur. J. Immunol. 25 (1995) 1843-1850
15. Balla-Jhagjhoorsingh S.S., Koopman G., Mooij P., Haaksma T.G.M., Teeuwsen V.J.P., Bontrop R.E., and Heeney J.L. Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees. J. Immunol. 162 (1999) 2308-2314
16. Banda N.K., Bernier J., Kurahara D.K., Kurrle R., Haigwood N., Sekaly R.P., and Finkel T.H. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J. Exp. Med. 176 (1992) 1099-1106
17. Barber L.D., Bal V., Lamb J.R., O'Hehir R.E., Yendle J., Hancock R.J.T., and lechler R.I. Contribution of T-cell receptor-contacting and peptide-binding residues of the class II molecule HLA-DR4 Dw10 to serologic and antigen-specific T cell recognition. Hum. Immunol. 32 (1991) 110-118
18. Barbouche R., Decroly E., Kieny M.P., and Fenouillet E. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the Env precursor interferes with membrane fusion at a post-CD4 binding step. Virology 273 (2000) 169-177
19. Barbouche R., Feyfant E., Belhaj B., and Fenouillet E. Pharmacophore determination of a gp120 C terminal-derived anti-HIV peptide construct interfering with membrane fusion suggesting that processing of the gp120 C terminus is a prelude to fusion. AIDS Res. Hum. Retroviruses 18 (2002) 201-206
20. Barker E., Mackewicz C.E., Reyes-Teran G., Sato A., Stranford S.A., Fujimura S.H., Christopherson C., Chang S.Y., and Levy J.A. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 92 (1998) 3105-3114
21. Barrios A., Rendon A., Negredo E., Barreriro P., Garcia-benayas T., Labarga P., Santos J., Domingo P., Sanchez-Conde Maida I., Martin-Carbonero L., Nunez M., Blanco F., et al. Paradoxical CD4 T cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 19 (2005) 569-576
22. Beausejour Y., and Tremblay M.J. Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane. J. Infect. Dis. 190 (2004) 894-902
23. Benichou G., Valujskikh A., and Heeger P.S. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J. Immunol. 162 (1999) 352-358
24. Blanco J., Barretina J., Gutierrez A., Armand-Ugon M., Cabrera C., Clotet B., and Este J.A. Preferential attachment of HIV particles to activated and CD45RO+ CD4+ T cells. AIDS Res. Hum. Retroviruses 18 (2002) 27-38
25. Bleul C.C., Wu L., Hoxie J.A., Springer T.A., and Mackay C.R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94 (1997) 1925-1930
26. Bluestone J.A., Kaliyaperumal A., Jameson S., Miller S., and Dick R. Peptide-induced changes in class I heavy chains alter allorecognition. J. Immunol. 151 (1993) 3943-3953
27. Boldt-Houle D.M., Rinaldo C.R., and Erlich G.D. Random depletion of T cells that bear specific T cell receptor Vβ sequences in AIDS patients. J. Leukoc. Biol. 54 (1993) 486-491
28. Bontrop R.E., and Watkins D.I. MHC polymorphism: AIDS susceptibility in non-human primates. Trends Immunol. 26 (2005) 227-233
29. Bounou S., Dumais N., and Tremblay M.J. Attachment of human immunodeficiency virus-1 (HIV-1) particles bearing host encoded B7-2 proteins leads to nuclear factor-kB- and nuclear factor of activated T-cells-dependent activation of HIV-1 long terminal repeat transcription. J. Biol. Chem. 276 (2001) 6359-6369
30. Boytim M.L., Lyu S.C., Jung R., Krensky A.M., and Clayberger C. Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65-79 of an HLA class II sequence: Functional similarities but mechanistic differences with the immunosuppressive drug rapamycin. J. Immunol. 160 (1998) 2215-2222
31. Brander C., Hartman K.E., Trocha A.K., Jones N.G., Johnson R.P., Korber B., Wentworth P., Buchbinder S.P., Wolinsky S., Walker B.D., and Kalams S.A. Lack of strong immune selection pressure by the immunodominant HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J. Clin. Invest. 101 (1998) 2559-2566
32. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., Nguyen P.L., Khoruts A., Larson M., Haase A.T., and Douek D.C. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200 (2004) 749-759
33. Brenchley J.M., Price D.A., and Douek D.C. HIV disease: Fallout from a mucosal catastrophe?. Nat. Immunol. 7 (2006) 235-239
34. Brenchley J.M., Price D.A., Schacker T.W., Asher T.E., Silvestri G., Rao S., Kazzaz Z., Bornstein E., Lambotte O., Altmann D., Blazar B.R., Rodriguez B., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12 (2006) 1365-1371
35. Brinchmann J.E., Albert J., and Vartdal F. Few infected CD4+ T cells but a high proportion of replication competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection. J. Virol. 65 (1991) 2019-2023
36. Brinkworth R.I. The envelope glycoprotein of HIV-1 may have incorporated the CD4 binding site from HLA-DQβ1. Life Sci. 45 (1989) iii-ix
37. Brown L., Souberbielle B.E., Marriott J.B., Westby M., Desselberger U., Kaye T., Gougeon M.L., and Dalgleish A. The conserved carboxy terminal region of HIV-1 gp120 is recognised by seronegative HIV-exposed people. AIDS 13 (1999) 2515-2521
38. Butera S.T., Roberts B.D., and Folks T.M. Regulation of HIV-1 expression by cytokine networks in a CD4+ model of chronic infection. J. Immunol. 150 (1993) 625-634
39. Cadogan M., Austen B., Heeney J., and Dalgleish A.G. HLA homology within the C5 domain promotes peptide binding by HIV-1 gp120. AIDS Res. Hum. Retroviruses 24 (2008) 845-885
40. Callahan L.N., Roderiquez G., Mallinson M., and Norcross M.A. Analysis of HIV induced autoantibodies to cryptic epitopes on human CD4. J. Immunol. 149 (1992) 2194-2202
41. Cantin R., Fortin J.F., and Tremblay M. The amount of host HLA-DR proteins acquired by HIV-1 is virus strain and cell type specific. Virology 218 (1996) 372-381
42. Cantin R., Fortin J.F., Lamontagne G., and Tremblay M. The acquisition of host derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human T-lymphoid cells. Blood 90 (1997) 1091-1100
43. Cantin R., Martin R., and Tremblay M.J. A novel virus capture assay reveals a differential acquisition of host HLA-DR by clinical isolates of human immunodeficiency virus type 1 expanded in primary human cells depending on the nature of producing cells and the donor source. J. Gen. Virol. 82 (2001) 2979-2987
44. Cantin R., Methot S., and Tremblay M.J. Plunder and stowaways: Incorporation of cellular proteins by enveloped viruses. J. Virol. 79 (2005) 6577-6587
45. Carrington M., Nelson G., Martin M.P., Kissner T., Vlahiv D., Goedert J.J., Kaslow R., Buchbinder S., Hoots K., and O'Brien S.J. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science 283 (1999) 1748-1752
46. Carrington M., Nelson G., and O'Brien S.J. Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunol. Lett. 79 (2001) 131-140
47. Castilletti C., Capobianchi M.R., Fais S., Abbate I., Ficociello B., Ameglio F., Cordiali Fei P., Santini S.M., and Dianzani F. HIV type 1 grown on interferon γ-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells. AIDS Res. Hum. Retroviruses 11 (1995) 547-553
48. Chicz R.M., Urban R.G., Lane W.S., Gorga J.C., Stern L.J., Vignali A.A., and Strominger J.L. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and heterogenous in size. Nature 358 (1993) 764-768
49. Chicz R.M., Urban R.G., Gorga J.C., Vignali A.A., Lane W.S., and Strominger J.L. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178 (1993) 27-47
50. Choi B.S., Park Y.K., and Lee J.S. The CD28/ HLA-DR expressions on CD4+ T but not CD8+ T cells are significant predictors for progression to AIDS. Clin. Exp. Immunol. 127 (2002) 137-144
51. Choudhary S.K., Vrisekoop N., Jansen C.A., Otto S.A., Schuitmaker H., Miedema F., and Camerini D. Low immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease. J. Virol. (2007) [Epub ahead of print]
52. Cibotti R., Kanellopoulos J.M., Cabaniols J.P., Halle-Panenko O., Kosmatopoulos K., Sercarz E., and Kourilsky P. Tolerance to a self protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 89 (1992) 416-420
53. Cicala C., Arthos J., Censoplano N., Cruz C., Chung E., Martinelli E., Lempicki R.A., Natarajan V., VanRyk D., Daucher M., and Fauci A.S. HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T cells. Virology 345 (2005) 105-114
54. Claus R., Hausmann S., Zavazava N., Walzel H., Schulze H.A., Kohler H.J., Friemel H., and Muller-Ruchholtz W. In vitro effects of solubilized HLA DR. Role in immunoregulation?. Cell. Immunol. 155 (1994) 476-485
55. Clerici M., Shearer G., hounsell E.F., Jameson B., Habeshaw J., and Dalgleish A.G. Alloactivated cytotoxic T cells recognize the carboxy terminal domain of human immunodeficiency virus-1 gp120 envelope glycoprotein. Eur. J. Immunol. 23 (1993) 2022-2025
56. Clerici M., Butto S., Lukwiya M., Saresella M., Declich S., Trabattoni D., Pastori C., Piconi S., Fracasso C., Fabiani M., Ferrante P., Rizzardini G., et al. Immune activation in Africa is environmentally-driven and is associated with up regulation of CCR5. AIDS 14 (2000) 2083-2092
57. Cohen G.B., Gandhi R.T., Davis D.M., Mandelboim O., Chen B.K., Strominger J.L., and Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 infected cells from NK cells. Immunity 10 (1999) 661-671
58. Cohen Stuart J.W., Hazenberg M.D., Hamann D., Otto S.A., Borleffs J.C., Miedema F., Boucher C.A., and De Boer R.J. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J. Acquir. Immune Defic. Syndr. 25 (2000) 203-211
59. Cosma A., Blanc D., Braun J., Quillent C., Barassi C., Moog C., Klasen S., Spire B., Scarlatti G., Pesenti E., Siccardi A.G., and Beretta A. Enhanced HIV infectivity and changes in gp120 conformation associated with viral incorporation of human leukocyte antigen class I molecules. AIDS 13 (1999) 2033-2042
60. Cottrez F., Manca F., Dalgleish A.G., Arenzana-Seisdedos F., Capron A., and Groux H. Priming of human antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two step mechanism involving the gp120 molecule. J. Clin. Invest. 99 (1997) 257-266
61. Daar E.S., Moudgil T., Meyer R.D., and Ho D.D. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324 (1991) 961-964
62. Dalgleish A.G. Autoimmune mechanisms of depletion of CD4 cells in HIV infection. Br. J. Haematol. 91 (1995) 525-534
63. Dalgleish A.G. Pathogenesis of AIDS and the importance of HLA. Semin. Clin. Immunol. 12 (1996) 31-39
64. Dalgleish A.G., Hounsell E., and Baum H. The potential role of HLA mimicry in the pathogenesis of AIDS. In: Dalgleish A.G., and Weiss R.A. (Eds). HIV and the New Viruses. 2nd edn (1999), Academic press 173-188
65. Dalgleish A.G., Marriott J.B., Souberbielle B., Montesana C., Sheikh J., Sidebottom D., Westby M., and Austen B. The role of HIV gp120 in the disruption of the immune system. Immunol. Lett. 66 (1999) 81-87
66. Davis I.C., Girard M., and Fultz P.N. Loss of CD4+ T cells in human immunodeficiency virus type 1 infected chimpanzees is associated with increased lymphocyte apoptosis. J. Virol. 72 (1998) 4623-4632
67. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006) 350-354
68. Deeks S.G., Kitchen C.M.R., Liu L., Guo H., Gascon R., Narvaez A.B., Hunt P., Martin J.N., Kahn J.O., Levy J., Mcgrath M.S., and Hecht F.M. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104 (2004) 942-947
69. De Groot N.G., Otting N., Doxiadis G.G.M., Balla-Jhagjhoorsingh S.S., Heeney J.L., Van Rood J.J., Gagneux P., and Bontrop R.E. Evidence for an ancient selective sweep in the MHC class I gene repertoire of chimpanzees. Proc. Natl. Acad. Sci. USA 99 (2002) 11748-11753
70. De Koster H.S., Anderson D.C., and Termijtelen A. T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP. J. Exp. Med. 169 (1989) 1191-1196
71. De Koster H.S., Van Rood J.J., and Termijtelen A. HLA-DR peptide induced alloreactive T cell lines reveal an HLA-DR sequence that can be both "dominant" and "cryptic": Evidence for allele-specific processing. Eur. J. Immunol. 22 (1992) 1531-1539
72. Demarest J.F., Jack N., Cleghorn F.R., Greenberg M.L., Hoffman T.L., Ottinger J.S., Fantry L., Edwards J., O'Brian T.R., Cao K., Mahabir B., Blattner W.A., et al. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res. Hum. Retroviruses 17 (2001) 1333-1344
73. Demberg T., Florese R.H., Gomez-Roman V.P., Larsen K., Van Rompay K.K.A., Marthas M.L., Venzon D., Kalyanaraman V.S., Pal R., Barnett S.W., Cafaro A., Ensoli B., et al. Non-neutralizing antibodies and vaccine-induced protection. Retrovirology 3 Suppl. 1 (2006) S26
74. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalvanaraman V.S., Lee E.M., Pal R., Venzon D., Grant R., Patterson L.J., Korioth-Schmitz B., et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 81 (2007) 3414-3427
75. De Roda Husman A.M., Van Rij R.P., Blaak H., Broersen S., and Schuitemaker H. Adaption to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J. Infect. Dis. 180 (1999) 1106-1115
76. De Santis C., Lopalco L., Robbioni P., Longhi R., Rappocciolo G., Siccardi A.G., and Beretta A. Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells. AIDS Res. Hum. Retroviruses 10 (1994) 157-162
77. De Santis C., Robbioni P., Longhi R., Carrow E., Siccardi A.G., and Beretta A. Role of HLA class I in HIV type 1-induced syncytium formation. AIDS Res. Hum. Retroviruses 12 (1996) 1031-1040
78. Di Marzo Veronese F., Arnott D., Barnaba V., Loftus D.J., Sakaguchi K., Thompson C.B., Selemi S., Mastroianni C., Sette A., Shabanowitz J., Hunt D.F., and Appella E. Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type-1 infected subjects. J. Exp. Med. 183 (1996) 2509-2516
79. Dimitrov D.S., Willey R.L., Sato H., Chang L.J., Blumenthal R., and Martin M.A. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 67 (1993) 2182-2190
80. Di Rienzo A.M., Furlini G., Olivier R., Ferris S., Heeney J., and Montagnier L. Different proliferative response of human and chimpanzee lymphocytes after contact with human immunodeficiency virus type 1 gp120. Eur. J. Immunol. 24 (1994) 34-40
81. Doisne J.M., Urrutia A., Lacabaratz-Porret C., Goujard C., Meyer L., Chaix M.L., Sinet M., and Venet A. CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J. Immunol. 173 (2004) 2410-2418
82. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., Casazza J.P., Kuruppu J., Kunstman K., Wolinsky S., Grossman Z., Dybul M., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 (2002) 95-98
83. Duesberg P. Human immunodeficiency virus and acquired immunodeficiency syndrome: Correlation but not causation. Proc. Natl. Acad. Sci. USA 86 (1989) 755-764
84. Duesberg P., and Rasnick D. The AIDS dilemma: Drug diseases blamed on a passenger virus. Genetica 104 (1998) 85-132
85. Duh E.J., Maury W.J., Folks T.M., Fauci A.S., and Rabson A.B. Tumour necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 86 (1989) 5974-5978
86. Dunham R., Pagliardini P., Gordon S., sumpter B., Engram J., Moanna A., Paiardini M., Mandl J.N., Lawson B., Garg S., Mcclure H., Xu Y.X., et al. The AIDS-resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood 108 (2006) 209-217
87. Duvall M.G., Jaye A., Dong T., Brenchley J.M., Alabi A.S., Jefferies D.J., Van Der Sande M., Togun T.O., McConkey S.J., Douek D.C., McMichael A.J., Whittle H.C., et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J. Immunol. 176 (2006) 6973-6981
88. Editorial. AIDS: How can a pussycat kill?. Lancet 339 (1992) 839-840
89. Eggena M.P., Barugahare B., Jones N., Okello M., Mutalya S., Kityo C., Mugyenyi P., and Cao H. Depletion of regulatory T cells in HIV infection is associated with immune activation. J. Immunol. 174 (2005) 4407-4414
90. Embretson J., Zupancic M., Ribas J.L., Burke A., Racz P., Tenner-Racz K., and Haase A.T. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362 (1993) 359-362
91. Essajee S.M., Pollack H., Rochford G., Oransky I., Krasinski K., and Borkowsky W. Early changes in quasispecies repertoire in HIV-infected infants: Correlation with disease progression. AIDS Res. Hum. Retroviruses 16 (2000) 1949-1957
92. Esser M.T., Grahen D.R., Coren L.V., Trubay C.M., Bess J.W., Arthur L.O., Ott D.E., and Lifson J.D. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2) and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: Implications for viral pathogenesis and immune regulation. J. Virol. 75 (2001) 6173-6182
93. Esser M.T., Bess J.W., Suryanarayana K., Chertova E., Marti D., Carrington M., Arthur L.O., and Lifson J.D. Partial activation and induction of apoptosis in CD4+ and CD8+ T lymphocytes by conformationally authentic non-infectious human immunodeficiency virus type 1. J. Virol. 75 (2001) 1152-1164
94. Estaquier J., Idziorek T., De Bels F., Barré-Sinoussi F., Hurtrel B., Aubertin A.M., Venet A., Mehtali M., Muchmore E., Michel P., Mouton Y., Girard M., et al. Programmed cell death and AIDS: Significance of T-cell apoptosis in pathogenic and non-pathogenic primate lentiviral infections. Proc. Natl. Acad. Sci. USA 91 (1994) 9431-9435
95. Estes J.D., Reynolds M.R., Wietgrefe S., Duan L., Schacker T., Picker L.J., Watkins D.I., Lifson J.D., Reilly C., Carlis J., and Haase A.T. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J. Infect. Dis. 193 (2006) 703-712
96. Esteves A., Piedade J., Santos C., Venenno T., Canas-Ferreira W.F., and Parreira R. Follow-up study of intrahost HIV type 2 variability reveals discontinuous evolution of C2V3 sequences. AIDS Res. Hum. Retroviruses 17 (2001) 253-256
97. Fahey J.L., Taylor J.M.G., Manna B., Nishanian P., Aziz N., Giorgi J.V., and Detels R. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 12 (1998) 1581-1590
98. Fahnestock M.L., Johnson J.L., Feldman R.M., Neveu J.M., Lane W.S., and Bjorkman P.J. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity 3 (1995) 583-590
99. Fernandez S., Price P., McKinnon E.J., Nolan R.C., and French M.A. Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function. Clin. Immunol. 120 (2006) 163-170
100. Finkel T.H., Tudor-Williams G., Banda N.K., Cotton M.F., Curiel T., Baba T.W., Ruprecht R.M., and Kupfer A. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med. 1 (1995) 129-134
101. Fischer Lindahl K., and Wilson D.B. Histocompatibility antigen-activated cytotoxic T Lymphocytes. Estimates of the frequency and specificity of precursors. J. Exp. Med. 145 (1977) 508-522
102. Fortin J.F., Cantin R., Lamontagne G., and Tremblay M. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J. Virol. 71 (1997) 3588-3596
103. Fortin J.F., Cantin R., and Tremblay M.J. T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1. J. Virol. 72 (1998) 2105-2112
104. Foster S., Beverley P., and Aspinall R. Gp120-induced programmed cell death in recently activated T cells without subsequent ligation of the T cell receptor. Eur J. Immunol. 25 (1995) 1778-1782
105. Freese A., and Zavazava N. HLA-B7 β-pleated sheet-derived synthetic peptides are immunodominant T-cell epitopes regulating alloresponses. Blood 99 (2002) 3286-3292
106. Fu X.T., Bono C.P., Woulfe S.L., Swearingen C., Summers N.L., Sinigaglia F., Sette A., Schwartz B.D., and Karr R.W. Pocket 4 of the HLA-DR(α,β1*0401) molecule is a major determinant of T cell recognition of peptide. J. Exp. Med. 181 (1995) 915-926
107. Gascon R.L., Navaez A.B., Zhang R., Kahn J.O., Hecht F.M., Herndier B.G., and McGrath M.S. Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. J. Acquir. Immune Defic. Syndr. 30 (2002) 146-153
108. Gelderblom H.R., Reupke H., and Pauli G. Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis?. Lancet 2 (1985) 1016-1017
109. George M.D., Verhoeven D., McBride Z., and Dandekar S. Gene expression profiling of gut mucosa and mesenteric lymph nodes in simian immunodeficiency virus-infected macaques with divergent disease course. J. Med. Primatol. 35 (2006) 261-269
110. Ghio M., Contini P., Mazzei C., Brenci S., Barberis G., Filaci G., Indiveri F., and Puppo F. Soluble HLA class I, HLA class II, and Fas ligand in blood components: A possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 93 (1999) 1770-1777
111. Giorgi J.V., Liu Z., Hultin L.E., Cumberland W.G., Hennessey K., and Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: Results of 6 years of follow up. The Los Angeles Center, multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 6 (1993) 904-912
112. Giorgi J.V., Hultin L.E., McKeating J.A., Johnson T.D., Owens B., Jacobson L.P., Shih R., Lewis J., Wiley D.J., Phair J.P., Wolinsky S.M., and Detels R. Shorter survival in advanced human immunodeficiency virus type 1 is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179 (1999) 859-870
113. Golding H., McCluskey J., Munitz T.I., Germain R.N., Margulies D.H., and Singer A. T-cell recognition of a chimaeric class II/class I MHC molecule and the role of L3T4. Nature 317 (1985) 425-427
114. Golding H., Robey F.A., Gates F.T., Linder W., Beining P.R., Hoffmann T., and Golding B. Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC II β1 domain. J. Exp. Med. 167 (1988) 914-923
115. Golding H., Shearer G.M., Hillman K., Lucas P., Manischwitz J., Zajac R.A., Clerici M., Gress R.E., Boswell R.N., and Golding B. Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J. Clin. Invest. 83 (1989) 1430-1435
116. Goldstein S., Ourmanov I., Brown C.R., Beer B.E., Elkins W.R., Plishka R., Buckler-White A., and Hirsch V.M. Wide range of viral load in healthy African green monkeys naturally infected with simian immunodeficiency virus. J. Virol. 74 (2000) 11744-11753
117. Gougeon M.L. Apoptosis as an HIV strategy to escape immune attack. Nat. Rev. Immunol. 3 (2003) 392-404
118. Gougeon M.L., Lecoeur H., Dulioust A., Enouf M.G., Crouvoisier M., Goujard C., Debord T., and Montagnier L. Programmed cell death in peripheral lymphocytes from HIV-infected persons. Increased susceptibility to apoptosis of CD4+ and CD8+ T cells correlates with lymphocyte activation and with disease progression. J. Immunol. 156 (1996) 3509-3520
119. Gougeon M.L., Lecoceur H., Boudet F., Ledru E., Marzabal S., Boullier S., Roue R., Nagata S., and Heeney J. Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95-induced apoptosis and presence of a T helper 1 phenotype. J. Immunol. 158 (1997) 2964-2976
120. Goulder P.J.R., Brander C., Tang Y., Tremblay C., Colbert R.A., Addo M.M., Rosenberg E.S., Nguyen T., Allen R., Trocha A., Altfeld M., He S., et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412 (2001) 334-337
121. Grant M.D., Smaill F.M., and Rosenthal K.L. Lysis of CD4+ lymphocytes by non-HLA restricted lymphocytes from HIV-infected individuals. Clin. Exp. Immunol. 93 (1993) 356-362
122. Grant M., Smaill F., Muller S., Kohler H., and Rosenthal K. The anti-idiotypic antibody 1F7 selectively inhbits cytotoxic T cells activated in HIV-1 infection. Immunol. Cell Biol. 78 (2000) 20-27
123. Grassi F., Meneveri R., Gullberg M., Lopalco L., Rossi G.B., De Santis L., Brattsand G., Butto S., Ginelli E., Beretta A., and Siccardi A.G. Human immunodeficiency virus type 1 gp120 mimics a hidden polymorphic epitope borne by class I major histocompatibility complex heavy chains. J. Exp. Med. 174 (1991) 53-62
124. Green S.J. Gut Mucosa in HIV infection: "immune milk" solution. PLoS Med. 4 (2007) 392-393
125. Greenough T.C., Somasundaran M., Brettler D.B., Hesselton R.M., Alimenti A., Kirchhoff F., Panicali D., and Sullivan J.L. Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 10 (1994) 395-403
126. Greenough T.C., Brettler D.B., Kirchhoff F., Alexander L., Desrosiers R.C., O'Brien S.J., Somasundaran M., Luzuriaga K., and Sullivan J.L. Long-Term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort. J. Infect. Dis. 180 (1999) 1790-1802
127. + T-cell depletion in HIV infection: Are we closer to understanding the cause?. Nat. Med. 8 (2002) 319-323
128. Grossman Z., Meier-Schellersheim M., Paul W.E., and Picker L.J. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat. Med. 12 (2006) 289-295
129. Groux H., Torpier G., Monte D., Mouton Y., Capron A., and Amiesen J.C. Activation-induced cell death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J. Exp. Med. 175 (1992) 331-340
130. Guadalupe M., Reay E., Sankaran S., Prindiville T., Flamm J., McNeil A., and Dandekar S. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77 (2003) 11708-11717
131. Guadalupe M., Sankaran S., George M.D., Reav E., verhoeven D., Shacklett B.L., Flamm J., Wegelin J., Prindiville T., and Dandekar S. Viral Suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J. Virol. 80 (2006) 8236-8247
132. Gurley R.J., Ikeuchi K., Byrn R.A., Anderson K., and Groopman J.E. CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA 86 (1989) 1993-1997
133. Habeshaw J.A. HLA mimicry by HIV-1 gp120 in the pathogenesis of AIDS. Immunol. Today 15 (1994) 39-40
134. Habeshaw J., Hounsell E., and Dalgleish A. Does the HIV envelope induce a chronic graft-versus-host-like disease?. Immunol. Today 13 (1992) 207-210
135. Habeshaw J.A., Wilson S.E., Hounsell E.F., and Oxford J.S. How HIV-1 lentivirus causes immune deficiency disease. Med. Hypotheses 52 (1999) 59-67
136. Harper M.E., Marselle L.M., Gallo R.C., and Wong-Staal F. Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc. Natl. Acad. Sci. USA 83 (1986) 772-776
137. Hay C.M., Ruhl D.J., Basgoz N.O., Wilson C.C., Billingsley J.M., DePasquale M.P., D'Aquila R.T., Wolinsky S.M., Crawford J.M., Montefiori D.C., and Walker B. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J. Virol. 73 (1999) 5509-5519
138. Hazenberg M.D., Otto S.A., Van Benthem B.H.B., Roos M.T.L., Coutinho R.A., Lange J.M.A., Hamann D., Prins M., and Miedema F. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17 (2003) 1881-1888
139. Herbein G., Mahlknecht U., Batliwalla F., Gregersen P., Pappas T., Butler J., O'Brien W.A., and Verdin E. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395 (1998) 189-194
140. Hickman H.D., Luis A.D., Bardet W., Buchli R., Battson C.L., Shearer M.H., Jackson K.W., Kennedy R.C., and Hildebrand W.H. Cutting edge: Class I presentation of host peptides following HIV infection. J. Immunol. 171 (2003) 22-26
141. Hickman-Miller H.D., Bardet W., Gilb A., Luis A.D., Jackson K.W., Watkins D.I., and Hildebrand W.H. Rhesus macaque MHC class I molecules present HLA-B-like peptides. J. Immunol. 175 (2005) 367-375
142. Hoffenbach A., Langlade-Demoyen P., Dadaglio G., Vilmer E., Michel F., Mayaud C., Autran B., and Plata F. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J. Immunol. 142 (1989) 452-462
143. Hoffmann G.W., Kion T.A., and Grant M.D. An idiotypic network model of AIDS immunopathogenesis. Proc. Natl. Acad. Sci. USA 88 (1991) 3060-3064
144. Holl V., Peressin M., Decoville T., Schmidt S., Zolla-Pazner S., Aubertin A.M., and Moog C. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J. Virol. 80 (2006) 6177-6181
145. Holm G.H., and Gabuzda D. Distinct mechanisms of CD4+ and CD8+ T cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J. Virol. 79 (2005) 6299-6311
146. Horton H., Frank I., Baydo R., Jalbert E., Penn J., Wilson S., McNevin J.P., McSweyn M.D., Lee D., Huang Y., De Rosa S.C., and McElrath M.J. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J. Immunol. 177 (2006) 7406-7415
147. Houlgatte R., Scarmato P., El Marhomy S., Martin M., Ostankovitch M., Lafosse S., Versisch A., Auffray C., and Platier-Tonneau D. HLA class II antigens and the HIV envelope glycoprotein gp120 bind to the same face of CD4. J. Immunol. 152 (1994) 4475-4488
148. Hounsell E.F., Renouf D.V., Liney D., Dalgelish A.G., and Habeshaw J.A. A proposed molecular model for the carboxy terminus of HIV-1 gp120 showing structural features consistent with the presence of a T-cell alloepitope. Mol. Aspects Med. 12 (1991) 283-296
149. Huber B.T., Beautner U., and Subramanyam M. The role of superantigens in the immunology of retroviruses. Ciba Found. Symp. 187 (1994) 132-140
150. Hunt P.W., Martin J.N., Sinclair E., Bredt B., Hagos E., Lampiris H., and Deeks S.G. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187 (2003) 1534-1543
151. Israel-Biet D., Venet A., Beldjord K., Andrieu J.M., and Even P. Autoreactive cytotoxicity in HIV-infected individuals. Clin. Exp. Immunol. 81 (1990) 18-24
152. Jameson S.C., and Bevan M.J. T-cell selection. Curr. Opin. Immunol. 10 (1998) 214-219
153. Jankovic V., Remus K., Molano A., and Nikolich-Zugich J. T cell recognition of an engineered MHC class I molecule: Implications for peptide-independent alloreactivity. J. Immunol. 169 (2002) 1887-1892
154. Jaye A., Sarge-Njie R., Van Der Loeff M.S., Todd J., Alabi A., Sabally S., Corrah T., and Whittle H. No differences in cellular immune responses between asymptomatic HIV type 1 and HIV type 2 infected Gambian patients. J. Infect. Dis. 189 (2004) 498-505
155. Jiang X., and Moudgil K.D. The unveiling of hidden T-cell determinants of a native antigen by defined mediators of inflammation: Implications for the pathogenesis of autoimmunity. Scand. J. Immunol. 63 (2006) 338-346
156. Jiang Y., Chen D., Lyu S.C., Ling X., Krensky A.M., and Clayberger C. DQ 65-79, a peptide derived from HLA class II, induces IκB expression. J. Immunol. 168 (2002) 3323-3328
157. Jonsson K., McDevitt D., McGavin M.H., Patti J.M., and Hook M. Staphylococcus aureus expressed a major histocompatibility complex class II analog. J. Biol. Chem. 270 (1995) 21457-21460
158. Jurcevic S., Praud C., Coppin H.L., Bertrand A., Ricard S., and Thomsen M. Role of polymorphic residues of huma leucocyte antigen-DR molecules on the binding of human immunodeficiency virus peptides. Immunology 87 (1996) 414-420
159. Kameoka M., Kimura T., Zheng Y.H., Suzuki S., Fujinaga K., Luftig R.B., and Ikuta K. Protease-defective, gp120-containing human immunodeficiency virus type 1 particles induce apoptosis more efficiently than does wild-type virus or recombinant gp120 protein in healthy donor-derived peripheral blood T cells. J. Clin. Microbiol. 35 (1997) 41-47
160. Karray S., and Zouali M. Identification of the B cell superantigen-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 94 (1997) 1356-1360
161. Kaslow R.A., Duquesnoy R., VanRaden M., Kingsley L., Marrari M., Friedman H., Su S., Saah A.J., Detels R., Phair J., and Rinaldo C. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. Lancet 335 (1990) 927-930
162. Kaslow R.A., Carrington M., Apple R., Park L., Munoz A., Saah A.J., Goedert J.J., Winkler C., O'Brien S.J., Rinaldo C., Detels R., Blattner W., et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2 (1996) 405-411
163. Katsikis P.D., Wunderlich E.S., Smith C.A., Herzenberg L.A., and Herzenberg L.A. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J. Exp. Med. 181 (1995) 2029-2036
164. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., Rathnavalu P., Moore C., Pfafferott K.J., Hilton L., Zimbwa P., Moore S., et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432 (2004) 769-774
165. Kinoshita S., Chen B.K., Kaneshima H., and Nolan G.P. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 98 (1998) 595-604
166. Kinter A.L., Horak R., Sion M., Riggin L., McNally J., Lin J., Jackson R., O'shea A., Roby G., Kovacs C., Conners M., Migueles S.A., et al. CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. AIDS Res. Hum. Retroviruses 23 (2007) 438-450
167. Kinter A., McNally J., Riggin L., Jackson R., Roby G., and Fauci A.S. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc. Natl. Acad. Sci. USA 104 (2007) 3390-3395
168. Klein M.R., Van Baalen C.A., Holwerda A.M., Garde S.R.K., Bende R.J., Keet I.P.M., Eeftinck-Schattenkerk J.K.M., Osterhaus A.D.M.E., Schuitemaker H., and Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181 (1995) 1365-1372
169. Koning F.A., Otto S.A., Hazenberg M.D., Dekker L., Prins M., Miedema F., and Schuitemaker H. Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J. Immunol. 175 (2005) 6117-6122
170. Koot M., Vos A.H.V., Keet R.P.M., De Goede R.E.Y., Dercksen M.W., Terpstra F.G., Coutinho R.A., Miedema F., and Termette M. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 6 (1992) 49-54
171. Kornfeld C., Ploquin M.J., Pandrea I., Faye A., Onanga R., Apetrei C., Poaty-Mayoungou V., Rouquet P., Estaquier J., Mortara L., Desoutter J.F., Butor C., et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J. Clin. Invest. 115 (2005) 1082-1091
172. Krensky A.M., and Clayberger C. HLA-derived peptides as novel immunotherapeutics. Clin. Immunol. Immunopathol. 75 (1995) 112-116
173. Kuo P.C., and Stock P.G. Transplantation in the HIV+ patient. Am. J. Transplant 1 1 (2001) 13-17
174. Kuzushima K., Sun R., Van Bleek G.M., Vegh Z., and Nathenson S.G. The role of self peptides in the allogeneic cross-reactivity of CTLs. J. Immunol. 154 (1995) 594-601
175. Lane H.C., Deper J.M., Greene W.C., Whalan G., Waldmann T.A., and Fauci A.S. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N. Engl. J. Med. 313 (1985) 79-84
176. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity?. J. Exp. Med. 181 (1995) 1945-1948
177. Lawn S.D., and Butera S.T. Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: Correlation with stage of disease and presence of opportunistic infection. J. Virol. 74 (2000) 10256-10259
178. Lawn S.D., Butera S., and Folks T.M. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin. Microbiol. Rev. 14 (2001) 753-777
179. Lehmann P.V., Forsthuber T., Miller A., and Sercarz E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358 (1992) 155-157
180. Lempicki R.A., Kovacs J.A., Baseler M.W., Adelsberger J.W., Dewar R.L., Nataranjan V., Bosche M.C., Metcalf J.A., Stevens R.A., Lambert L.A., Alvord W.G., Polis M.A., et al. Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc. Natl. Acad. Sci. USA 97 (2000) 13778-13783
181. Leng Q., Bentwich Z., Magen E., Kalinkovich G., and Borkow G. CTLA-4 upregulation during HIV infection: Association with anergy and possible therapeutic intervention. AIDS 16 (2002) 519-529
182. Lenz J., Su M., Mizrachi Y., Burke M., and Rubinstein A. V3 variation in HIV-seropositive patients receiving a V3-targeted vaccine. AIDS 15 (2001) 577-581
183. Li Q., Duan L., Estes J.D., Ma Z.M., Rourke T., Wang Y., Reilly C., Carlis J., Miller C.J., and Haase A.T. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434 (2005) 1148-1152
184. Liegler T.J., Yonemoto W., Elbeik T., Vittinghoff E., Buchbinder S.P., and Greene W.C. Diminished spontaneous apoptosis in lymphocytes from immunodeficiency virus-infected long-term nonprogressors. J. Infect. Dis. 178 (1998) 669-679
185. Lifson A.R., Buchbinder S.P., Sheppard H.W., Mawle A.C., Wilber J.C., Stanley M., Hart C.E., Hessol N.A., and Holmberg S.D. Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: Immunologic and virologic characteristics. J. Infect. Dis. 163 (1991) 959-965
186. Liu Z., Sun Y.K., Xi Y.P., Maffei A., Reed E., Harris P., and Suciu-Foca N. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J. Exp. Med. 177 (1993) 1643-1650
187. Liu S.L., Schacker T., Musey L., Shriner D., McElrath M.J., Corey L., and Mullins J.I. Divergent patterns of progression to AIDS after infection from the same source: Human immunodeficiency virus type 1 evolution and antiviral responses. J. Virol. 71 (1997) 4284-4295
188. Liu Z., Cumberland W.G., Hultin L.E., Prince H.E., Detels R., and Giorgi J.V. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 16 (1997) 83-92
189. Liu Z., Cumberland W.G., Hultin L.E., Kaplan A.H., Detels R., and Giorgi J.V. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 18 (1998) 332-340
190. Loomis-Price L.D., Cox J.H., Mascola J.R., Vancott T.C., Michael N.L., Fouts T.R., Redfield R.R., Robb M.L., Wahren B., Sheppard H.W., and Birx D.L. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J. Infect. Dis. 178 (1998) 1306-1316
191. Lopalco L., De Santis C., Meneveri R., Longhi R., Ginelli E., Grassi F., Siccardi A.G., and Beretta A. Human immunodeficiency virus type 1 C5 region mimics the HLA class 1 α1 peptide binding domain. Eur. J. Immunol. 123 (1993) 2016-2021
192. Losier M., Fortin J.F., Cantin R., Bergeron M.G., and Tremblay M.J. Virion-bound ICAM-1 and activated LFA-1: A combination of factors conferring resistance to neutralization by sera from human immunodeficiency virus type 1-infected individuals independently of the disease status and phase. Clin. Immunol. 108 (2003) 111-118
193. Macdonald K.S., Embree J., Nienga S., Nagelkerke N.J., Ngatia I., Mohammed Z., Barber B.H., Ndinya-Achola J., Bwayo J., and Plummer F.A. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J. Infect. Dis. 177 (1998) 551-556
194. Machuca A., Ding L., Taffs R., Lee S., Wood O., Hu J., and Hewlett I. HIV type 2 primary isolates induce a lower degree of apoptosis "in vitro" compared with HIV type 1 primary isolates. AIDS Res. Hum. Retroviruses 20 (2004) 507-520
195. Mahalingam M., Peakman M., Davies E.T., Pozniak A., McManus T.J., and Vergani D. T cell activation and disease severity in HIV infection. Clin. Exp. Immunol. 93 (1993) 337-343
196. Maksyutov A.Z., Bachinskii A.G., Bazhan S.I., Ryzhikov E.A., and Maksyutov Z.A. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines. J. Clin. Virol. 31S (2004) S26-S38
197. Mamula M.J. The inability to process a self-peptide allows autoreactive T cells to escape tolerance. J. Exp. Med. 177 (1993) 567-571
198. Manca F., Walker L., Newell A., Celada F., Habeshaw J.A., and Dalgleish A.G. Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells. Clin. Exp. Immunol. 88 (1992) 17-22
199. Manca F., Newell A., Valle M., Habeshaw J., and Dalgleish A.G. HIV-induced deletion of antigen specific T cell function is MHC restricted. Clin. Exp. Immunol. 87 (1992) 15-19
200. Martin G., and Tremblay M.J. HLA-DR, ICAM-1, CD40, CD40L and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo. Clin. Immunol. 11 (2004) 275-285
201. Mathe G. Will killing the last HIV-1 particle cure AIDS patients? Doesn't CMV activation and/or a graft versus host component of the disease, also have to be considered?. Biomed. Pharmacother 50 (1996) 185-206
202. Mattapallil J.J., Douek D.C., Hill B., Nishimura Y., Martin M., and Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434 (2005) 1093-1097
203. Mavligit G.M., Talpaz M., Hsia F.T., Wong W., Lichtiger B., Mansell P.W.A., and Mumford D.M. Chronic immune stimulation by sperm alloantigens: Support for the hypothesis that spermatozoa induce immune dysregulation in homosexual males. JAMA 251 (1984) 237-241
204. McAdam S.N., Boyson J.E., Liu X., Garber T.L., Hughes A.L., Bontrop R.E., and Watkins D.I. A uniquely high level of recombination at the HLA-B locus. Proc. Natl. Acad. Sci. USA 91 (1994) 5893-5897
205. McAdam S., Klenerman P., Tussey L., Rowland-Jones S., Lalloo D., Phillips R., Edwards A., Giangrande P., Brown A.L., Gotch F., and McMichael A. Immunogenic HIV variant peptides that bind to HLA-B8 can fail to stimulate cytotoxic T lymphocyte responses. J. Immunol. 155 (1995) 2729-2736
206. α. Recognition of an isolated MHC antigenic structure by allospecific T cells but not alloantibodies. J. Immunol. 140 (1988) 2081-2089
207. Mcdonald J.C., and Adamashvili I. Soluble HLA: A review of the literature. Hum. Immunol. 59 (1998) 387-403
208. McKeating J.A., McKnight A., and Moore J.P. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: Effects on infectivity and neutralization. J. Virol. 65 (1991) 852-860
209. McNeil A.J., Yap P.L., Gore S.M., Brettle R.P., McColl M., Wyld R., Davidson S., Weightman R., Richardson A.M., and Robertson J.R. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Q. J. Med. 89 (1996) 177-185
210. Mehandru S., Tenner-Racz K., Racz P., and Markowitz M. The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. J. Allergy Clin. Immunol. 116 (2005) 419-422
211. Messele T., Brouwer M., Girma M., Fontanet A.L., Miedema F., Hamann D., and Rinke de Wit T.F. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: Correlation with cell surface activation markers. Clin. Immunol. 98 (2001) 212-219
212. Meyerhans A., Dadaglio G., Langlade-Demoyen P., Frank R., Asjo B., Plata F., and Wain-Hobson S. In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur. J. Immunol. 27 (1991) 2037-2040
213. Michel P., Balde A.T., Roussilhon C., Aribot G., Sarthou J.L., and Gougeon M.L. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: Correlation of T cell apoptosis with β2 microglobulin concentration and disease evolution. J. Infect. Dis. 181 (2000) 64-75
214. Migueles S.A., Sabbaghian M.S., Shupert W.L., Bettinotti M.P., Marincola F.M., Martino L., Hallahan C.W., Selig S.M., Schwartz D., Sullivan J., and Connors M. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 97 (2000) 2709-2714
215. Misse D., Gajardo J., Oblet C., Religa A., Riquet N., Mathieu D., Yssel H., and Veas F. Soluble HIV-1 gp120 enhances HIV-1 replication in non-dividing CD4+ T cells, mediated via cell signalling and Tat cofactor overexpression. AIDS 19 (2005) 897-905
216. Moebius U., Clayton L.K., Abraham S., Diener A., Yunis J.J., Harrison S.C., and reinherz E.L. Human immunodeficiency virus gp120 binding C′ C′′ ridge of CD4 domain 1 is also involved in interaction with class II major histocompatibility complex molecules. Proc. Natl. Acad. Sci. USA 89 (1992) 12008-12012
217. Montefiori D.C., Cornell R.J., Zhou J.Y., Zhou J.T., Hirsch V.M., and Johnson P.R. Complement control proteins, CD46, CD55 and CD59, as common surface constituents of human and simian immunodeficiency virus and possible targets for vaccine protection. Virology 205 (1994) 82-92
218. Moore J.P., McKeating J.A., Weiss R.A., and Sattentau Q.J. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250 (1990) 1139-1142
219. Moore C.B., John M., James I.R., Christiansen F.T., Witt C.S., and Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296 (2002) 1439-1443
220. Muro-Cacho C.A., Pantaleo G., and Fauci A.S. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J. Immunol. 154 (1995) 5555-5566
221. Murphy B., and Krensky A.M. HLA-derived peptides as novel immunomodulatory therapeutics. J. Am. Soc. Nephrol. 10 (1999) 1346-1355
222. Murphy B., Magee C.C., Alexander S.I., Waaga A.M., Snoeck H.W., Vella J.P., Carpenter C.B., and Sayegh M.H. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J. Clin. Invest. 103 (1999) 859-867
223. Murphy B., Yu J., Jiao Q., Lin M., Chitnis T., and Sayegh M.H. A novel mechanism for the immunomodulatory functions of class II MHC-derived peptides. J. Am. Soc. Nephrol. 14 (2003) 1053-1065
224. Musey L.K., Krieger J.N., Hughes J.P., Schacker T.W., Corey L., and McElrath M.J. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J. Infect. Dis. 180 (1999) 278-284
225. Nag B., Wada H.G., Passmore D., Clark B.R., Sharma S.D., and McConnell H.M. Purified β-chain of MHC class II binds to CD4 molecules on transfected Hela cells. J. Immunol. 150 (1993) 1358-1364
226. Nag B., Wada H.G., Deshpande S.V., Passmore D., Kendrick T., Sharma S.D., Clark B.R., and McConnell H.M. Stimulation of T cells by antigenic peptide complexed with isolated chains of major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90 (1996) 1604-1608
227. Nilsson J., Kinloch-de-loes S., Granath A., Sonnerborg A., Goh L.E., and Andersson J. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. AIDS 21 (2007) 565-574
228. Nisini R., Aiuti A., Matricardi P.M., Fattorossi A., Ferlini C., Biselli R., Mezzaroma I., Pinter E., and D'Amelio R. Lack of evidence for a superantigen in lymphocytes from HIV-discordant monozygotic twins. AIDS 8 (1994) 443-449
229. Nyambi P.N., Gorny M.K., Bastiani L., Von Der Groen G., Williams C., and Zolla-Pazner S. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: A new strategy for studying the immunologic relatedness of HIV-1. J. Virol. 72 (1998) 9384-9391
230. Nyambi P.N., Mbah H.A., Burda S., Williams C., Gorny M.K., Nadas A., and Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 74 (2000) 7096-7107
231. Ohno S. How cytotoxic T cells manage to discriminate nonself from self at the nonapeptide level. Proc. Natl. Acad. Sci. USA 89 (1992) 4643-4647
232. Olsen G.P., and Shields J.W. Seminal lymphocytes, plasma and AIDS. Nature 309 (1984) 116-117
233. Olson R.R., De Magistris M.T., Di Tommaso A., and Karr R.W. Mutations in the third, but not the first or second hypervariable regions of DR(β1*0101) eliminate DR1-Restricted recognition of a pertussis toxin peptide. J. Immunol. 148 (1992) 2703-2708
234. O'Neil S.P., Novembre F.J., Brodie Hill A., Suwyn C., Hart C.E., Evans-Strickfaden T., Anderson D.C., De Rosayro J., Herndon J.G., Saucier M., and McClure H.M. Progressive infection in a subset of HIV-1-positive chimpanzees. J. Infect. Dis. 182 (2000) 1051-1062
235. Ostrowski M.A., Justement S.J., Catanzaro A., Hallahan C.A., Ehler L.A., Mizell S.B., Kuman P.N., Mican J.A., Chun T.W., and Fauci A.S. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J. Immunol. 161 (1998) 3195-3201
236. Oswald-Richter K., Grill S.M., Leelawong M., and Unutmaz D. HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. Eur. J. Immunol. 34 (2004) 1705-1714
237. Oswald-Richter K., Grill S.M., Shariat N., Leelawong M., Sundrud M.S., Haas D.W., and Unutmaz D. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2 (2004) 955-966
238. Ott D.E. Potential roles of cellular proteins in HIV-1. Rev. Med. Virol. 12 (2002) 359-374
239. Palker T.J., Matthews T.J., Clark M.E., Cianciolo G.J., Randall R.R., Langlois A.J., White G.C., Snyderman R., Bolognesi D.P., and Hayse B.F. A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc. Natl. Acad. Sci. USA 84 (1987) 2479-2483
240. Pantaleo G., Graziosi C., Demarest J.F., Butini L., Montroni M., Fox C.H., Orenstein J.M., Kotler D.P., and Fauci A.S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362 (1993) 355-358
241. Pantaleo G., Menzo S., Vaccarezza M., Graziosi C., Cohen O.J., Demarest J.F., Montefiori D., Orenstein J.M., Fox C., Schrager L.K., Margolick J.B., Buchbinder S., et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332 (1995) 209-216
242. Paquette J.S., Fortin J.F., Blanchard L., and Tremblay M.J. Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity. J. Virol. 72 (1998) 9329-9336
243. Parham P., Clayberger C., Zorn S.L., Ludwig D.S., Schoolnik G.K., and Krensky A.M. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the α2-domain of HLA-A2. Nature 325 (1987) 625-628
244. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., Precopio M.L., Schacker T., Roederer Douek D.C., and Koup R.A. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203 (2006) 2281-2292
245. Piatak Jr. M., Saag M.S., Yang L.C., Clark S.J., Kappes J.C., Luk K.C., Hahn B.H., Shaw G.M., and Lifson J.D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259 (1993) 1749-1754
246. Picker L.J., and Watkins D.I. HIV pathogenesis: The first cut is the deepest. Nat. Immunol. 6 (2005) 430-432
247. Plaeger S., Bass H.Z., Nishanian P., Thomas J., Aziz N., Detels R., King J., Cumberland W., Kemeny M., and Fahey J.L. The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. Clin. Immunol. 90 (1999) 238-246
248. Poignard P., Fouts T., Naniche D., Moore J.P., and Sattentau Q.J. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J. Exp. Med. 183 (1996) 473-484
249. Poignard P., Sabbe R., Picchio G.R., Wang M., Gulizia R.J., Katinger H., Parren P.W.H.U., Mosier D.E., and Burton D.R. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10 (1999) 431-438
250. Polycarpou A., Ntais C., Korber B.T., Erlich H.A., Winchester R., Krogstad P., Wolinsky S., Rostron T., Rowland-Jones S.L., Ammann A.J., and Ioannidis J.P.A. Association between maternal and infant class I and II HLA alleles and of their concordance with the risk of perinatal HIV type 1 transmission. AIDS Res. Hum. Retroviruses 18 (2002) 741-746
251. Popper S.J., Saar A.D., Travers K.U., Gueye-Ndiaye A., Mboup S., Essex M.E., and Kanki P.J. Lower human immunodeficiency virus (HIV) type 2 viral load reflects difference in pathogenicity of HIV-1 and HIV-2. J. Infect. Dis. 180 (1999) 1116-1121
252. Popper S.J., Saar A.D., Gueye-Ndiaye A., Mboup S., Essex M.E., and Kanki P.J. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: Low virus production in vivo. J. Virol. 74 (2000) 1554-1557
253. Posnett D.N., Kabak S., Hodtsev A.S., Goldberg E.A., and Asch A. T-cell antigen receptor Vβ subsets are not preferentially deleted in AIDS. AIDS 7 (1993) 625-631
254. Pugliese O., Viora M., Camponeschi B., Cordiali Fei P., Caprilli F., Chersi A., Evangelista M., Di Massimo A.M., and Corlizzi V. A gp120 HIV peptide with high similarity to HLA class II β chains enhances PPD-specific and autoreactive T cell activation. Clin. Exp. Immunol. 90 (1992) 170-174
255. Puppo F., Contini P., Ghio M., Brenci S., Scudeletti M., Filaci G., Ferrone S., and Indiveri F. Soluble human MHC class I molecules induce solule Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95)+ T lymphocytes. Int. Immunol. 12 (2000) 195-203
256. Quinn T.C., Wawer M.J., Sewankamo N., Serwadda D., Li C., Wabwire-Mangen F., Meehan M.O., Lutalo T., and Gray R.H. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 342 (2000) 921-929
257. Raghunathan R., Mundy T.M., Faust J., and Misra S. Allogeneic leukocyte and germ cell-indiced murine immunodeficiency. J. Immunol. 135 (1985) 2429-2431
258. Raposo G., Moore M., Innes D., Leijendekker R., Leigh-Brown A., Benaroch P., and Geuze H. Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic 3 (2002) 718-729
259. Rawson P.M., Molette C., Videtta M., Altieri L., Franceschini D., Donato T., Finocchi L., Propato A., Paroli M., Meloni F., Mastroianni C.M., d'Ettore G., et al. Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat. Med. 13 12 (2007) 1431-1439
260. Reeves J.D., and Doms R.W. Human immunodeficiency virus type 2. J. Gen. Virol. 83 (2002) 1253-1265
261. Resino S., Seoane E., Gutierrez M.D., Leon J.A., and Munoz-Fernandez M.A. CD4 (+) T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 42 (2006) 269-276
262. Rey-Cuille M.A., Berthier J.L., Bomsel-Demontoy M.C., Chaduc Y., Montagnier L., Hovanessian A.G., and Chakrabarti L.A. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J. Virol. 72 (1998) 3872-3886
263. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV-1 infection. Proc. Natl. Acad. Sci. USA 100 (2003) 4144-4149
264. Rieckmann P., Poli G., Fox C.H., Kehrl J.H., and Fauci A.S. Recombinant gp120 specifically enhances tumour necrosis factor-α production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J. Immunol. 147 (1991) 2922-2927
265. Rizzuto C.D., and Sodroski J.G. The contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J. Virol. 71 (1997) 4847-4851
266. Roda-Rani K.P., Pelluru D., and Kondapi A.K. A conserved molecular action of native and recombinant Epap-1 in inhibition of HIV-1 gp120 mediated viral entry. Arch. Biochem. Biophys. 456 (2006) 79-92
267. Roe D.L., Lewis R.E., and Cruse J.M. Association of HLA-DQ and -DR alleles with protection from or infection with HIV-1. Exp. Mol. Pathol. 69 (2000) 21-82
268. Roederer M., Dubs J.G., Anderson M.T., Raju P.A., and Herzenberg L.A. CD8 naïve T cell counts decrease progressively in HIV-infected adults. J. Clin. Invest. 95 (1995) 2061-2066
269. Roger M. Influence of host genes on HIV-1 disease progression. FASEB J. 12 (1998) 625-632
270. Root-Bernstein R. Antigenic complementarity between HIV and other AIDS-associated infections results in idiotype-antiidiotype antibody complexes that cross react with lymphocyte surface proteins. Vaccine 23 (2005) 2160-2163
271. Rosen-Bronson S., Yu W.Y., and Karr R.W. Polymorphic HLA-DR7β1 chain residues that are involved in T cell allorecognition. J. Immunol. 146 (1991) 4264-4270
272. Rossio J.L., Bess J., Henderson L.E., Cresswell P., and Arthur L.O. HLA class II on HIV particles is functional in superantigen presentation to human T cells: Implications for HIV pathogenesis. AIDS Res. Hum. Retroviruses 11 (1995) 1433-1439
273. Rothenhausler B., Dornmair K., and McConnell H.M. Specific binding of antigenic peptides to separate α and β chains of class II molecules of the major histocompatibility complex. Proc. Natl. Acad. Sci. USA 87 (1990) 352-354
274. Rotzschke O., Falk K., Faath S., and Rammensee H.G. On the nature of peptides involved in T cell alloreactivity. J. Exp. Med. 174 (1991) 1059-1071
275. Roy J., Martin G., Giguere J.F., Belanger D., Petrin M., and Tremblay M.J. HIV type 1 can act as an APC upon acquisition from the host cell of peptide-loaded HLA-DR and CD86 molecules. J. Immunol. 174 (2005) 4779-4788
276. Saifuddin M., Parker C.J., Peeples M.E., Gorny M.K., Zolla-Pazner S., Ghassemi M., Rooney I.A., Atkinson J.P., and Spear G.T. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182 (1995) 501-509
277. Saifuddin M., Hedayati T., Atkinson J.P., Holguin M.H., Parker C.J., and Spear G.T. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 78 (1997) 1907-1911
278. Saifuddin M., Spear G.T., Chang C.H., and Roeuck K.A. Expression of MHC class II in T cells is associated with increased HIV-1 expression. Clin. Exp. Immunol. 121 (2000) 324-331
279. Saksela K., Muchmore E., Girard M., Fultz P., and Baltimore D. High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1 infected chimpanzees. J. Virol. 67 (1993) 7423-7427
280. Salazar-Gonzalez J.F., Martinez-Meza O., Nishanian P., Aziz N., Shen L.P., Grosser S., Taylor J., Detels R., and Fahey J.L. Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection. J. Infect. Dis. 178 (1998) 423-430
281. Salemi S., Caporossi A.P., Boffa L., Longobardi M.G., and Barnaba V. HIV gp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing. J. Exp. Med. 181 (1995) 2253-2257
282. Sankaran S., Guadalupe M., Reay E., George M.D., Flamm J., Prindiville T., and Dandekar S. Gut mucosal T cell response and gene expression correlate with protection against disease in long-term HIV-1 infected nonprogressors. Proc. Natl. Acad. Sci. USA 102 (2005) 9860-9865
283. Schindler M., Wurfl S., Benaroch P., Greenough T.C., Daniels R., Easterbrook P., Brenner M., Munch J., and Kirchhoff F. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well conserved functions of human and simian immunodeficiency virus nef alleles. J. Virol. 77 (2003) 10548-10556
284. Schindler M., Munch J., Kutsch O., Li H., Santiago M.L., Bibollet-Ruche F., Muller-Trutwin M.C., Novembre F.J., Peeters M., Courgnaud V., Bailes E., Roques P., et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125 (2006) 1055-1067
285. Schindler M., Wildum S., Casartelli N., Doria M., and Kirchhoff F. Nef alleles from children with non-progressive HIV-1 infection modulate MHC-II expression more efficiently than those from rapid progressors. AIDS 21 (2007) 1103-1107
286. Schols D., and De Clercq E. Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production. J. Virol. 70 (1996) 4953-4960
287. Schramm B., Penn M.L., Palacios E.H., Grant R.M., Kirchhoff F., and Goldsmith M.A. Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J. Virol. 74 (2000) 9594-9600
288. Sekaly R.P. The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development?. J. Exp. Med. 205 1 (2008) 7-12
289. Setini A., Beretta A., De Santis C., Meneveri R., Martayan A., Mazzilli M.C., Appella E., Siccardi A.G., Natali P.G., and Giacomini P. Distinctive features of the α1-domain of HLA-C heavy chains free of β2-Microglobulin. Hum. Immunol. 46 (1996) 69-81
290. Shankarappa R., Gupta P., Learn G.H., Rodrigo A.G., Rinaldo C.R., Gorry M.C., Mullins J.I., Nara P.L., and Erlich G.D. Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology 241 (1998) 251-259
291. Shearer G.M. Allogeneic leukocytes as a possible factor in induction of aids in homosexual men. N. Engl. J. Med. 308 (1983) 223-224
292. Shearer G.M., and Rabson G.M. Semen and AIDS. Nature 308 (1984) 230
293. Shearer G.M., Bernstein D.C., Tung K.S., Via C.S., Redfield R., Salahuddin S.Z., and Gallo R.C. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J. Immunol. 137 (1986) 2514-2521
294. Sheikh J., Ongradi J., Austen B., and Dalgleish A.G. The gp120 envelope of HIV-1 binds peptides in a similar manner to human leukocyte antigens. AIDS 9 (1995) 1229-1235
295. Sheikh J., Souberbielle B., Westby M., Austen B., and Dalgleish A.G. HIV gp120 plus specific peptides are recognized in a similar way to specific HLA plus peptide by HLA restricted antigen specific cell lines. Viral Immunol. 13 (2000) 9-17
296. Sheppard H.W., Ascher M.S., McRae B., Anderson R.E., Lang W., and Allain J.P. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J. Acquir. Immune Defic. Syndr. 4 (1991) 704-712
297. Shoskes D.A., and Wood K.J. Indirect presentation of MHC antigens in transplantation. Immunol. Today 15 (1994) 32-38
298. Silvestri G., Sodora D.L., Koup R.A., Paiardini M., O'Neil S.P., McClure H.M., Staprans S.I., and Feinberg M.B. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18 (2003) 441-452
299. Silvestri G., Fedanov A., Germon S., Kozyr N., Kaiser W.J., Garber D.A., McClure H., Feinberg M.B., and Staprans S.I. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J. Virol. 79 (2005) 4043-4054
300. Simmons A., Aluvihare V., and McMichael A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 14 (2001) 763-777
301. Simmonds P., Beatson D., Cuthbert R.J.G., Watson H., Reynolds B., Peutherer J.F., Parry J.V., Ludlum C.A., and Steel C.M. Determinants of HIV disease progression: Six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet 338 (1991) 1159-1163
302. Slifka M.K., Blattman J.N., Sourdive D.J., Liu F., Huffman D.L., Wolfe T., Hughes A., Oldstone M.B., Ahmed R., and Von Herrath M.G. Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy. J. Immunol. 170 (2003) 1231-1239
303. Smith P.A., Brunmark A., Jackson M.R., and Potter T.A. Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J. Exp. Med. 185 (1997) 1023-1033
304. Sonnabend J., Witkin S.S., and Purtilo D.T. Acquired immunodeficiency syndrome, opportunistic infections and malignancies in male homosexuals: A hypothesis of etiologic factors in pathogenesis. JAMA 249 (1983) 2370-2374
305. Sousa A.E., Carneiro J., Meier-Schellersheim M., Grossman Z., and Victorino R.M.M. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 169 (2002) 3400-3406
306. Spina C.A., Prince H.E., and Richman D.D. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J. Clin. Invest. 99 (1997) 1774-1785
307. Steinbrook R. One step forward, two steps back-Will there ever be an AIDS vaccine?. N. Engl. J. Med. 357 26 (2007) 2653-2655
308. Stumptner-Cuvelette P., Morchoisne S., Dugast M., Le Gall S., Raposo G., Schwartz O., and Benaroch P. HIV-1 nef impairs MHC class II antigen presentation and surface expression. Proc. Natl. Acad. Sci. USA 21 (2001) 12144-12149
309. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., and Turka L.A. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question. J. Immunol. 166 (2001) 973-981
310. Sumpter B., Dunham R., Gordon S., Engram J., Hennessy M., Kinter A., Paiardini M., Cervasi B., Klatt N., McClure H., Milush J.M., Staprans S., et al. Correlates of preserved CD4(+) T cell homeostatis during natural, nonpathogenic simian immunodeficiency virus infection of sooty mangabeys: Implications for AIDS pathogenesis. J. Immunol. 178 (2007) 1680-1691
311. Susal C., Kropelin M., Daniel V., and Opelz G. Molecular mimicry between HIV-1 and antigen receptor molecules: A clue to the pathogenesis of AIDS. Vox Sang. 65 (1993) 10-17
312. Teeuwsen V.J.P., Siebelink K.H.J., De Wolf F., Goudsmit J., Uytdehaag G.C.M., and Osterhaus D.M.E. Impairment of in vitro immune responses occurs within 3 months after HIV-1 seroconversion. AIDS 4 (1990) 77-81
313. Tesselaar K., Arens R., Van Schijndel G.M.W., Baars P.A., Van Der Valk M.A., Borst J., Van Oers M.H.J., and Van Lier R.A.W. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat. Immunol 4 (2003) 49-54
314. Thompson C.B., and Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 7 (1997) 445-450
315. Tian H., Lempicki R., King L., Donoghue E., Samelson L.E., and Cohen D.I. HIV envelope-directed signaling aberrancies and cell death of CD4+ T cells in the absence of TCR co-stimulation. Int. Immunol. 8 (1996) 65-74
316. Trachtenberg E., Korber B., Sollars C., Kepler T.B., Hraber P.T., Hayes E., Funkhouser R., Fugate M., Theiler J., Hsu Y.S., Kunstman K., Wu S., et al. Advantage of rare HLA supertype in HIV disease progression. Nat. Med. 9 (2003) 928-935
317. Tremblay M.J., Fortin J.F., and Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol. Today 19 (1998) 346-351
318. Trubey C.M., Chertova E., Coren L.V., Hilburn J.M., Hixson C.V., Nagashima K., Lifson J.D., and Ott D.E. Quantitation of HLA class II protein incorporated into human immunodeficiency virus type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles. J. Virol. 77 (2003) 12699-12709
319. Tung K.S.K., Koster F., Bernstein D.C., Kriebel P.W., Payne S.M., and Shearer G.M. Elevated allogeneic cytotoxic T lymphocyte activity in peripheral blood of lymphocytes of homosexual men. J. Immunol. 135 (1985) 3163-3171
320. Vahlne A., Horal P., Eroksson K., Jeansson S., Rymo L., Hedstrom K.G., and Czerkinsky C. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition. Proc. Natl. Acad. Sci. USA 88 (1991) 10744-10748
321. Vesanen M., Stevens C.E., Taylor P.E., Rubinstein P., and Saksela K. Stability in controling viral replication identifies long-term non-progressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons. J. Virol. 70 (1996) 9035-9040
322. Via C.S., Morse H.C., and Shearer G.M. Altered immunoregulation and autoimmune aspects of HIV infection: Relevant murine models. Immunol. Today 11 (1990) 250-255
323. Vlahakis S.R., Algeciras-Schimnich A., Bou G., Heppelmann C.J., Villasis-Keever A., Collman R.G., and Paya C.V. Chemokine-receptor activation by env determines the mechanism of death in HIV-infected and uninfected T lymphocytes. J. Clin. Invest. 107 (2001) 207-215
324. Warren R.Q., Wolf H., Zajac R.A., Boswell R.N., Kanda P., and Kennedy R.C. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels. J. Clin. Immunol. 11 (1991) 13-21
325. Watanabe M., Ringler D.J., Fultz P.N., Mackey J.J., Boyson J.E., Levine C.G., and Letvin N.L. A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. J. Virol. 65 (1991) 3344-3348
326. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
327. Weinhold K.J., Lyerly H.K., Stanley S.D., Austin A.A., Matthews T.J., and Bolognesi D.P. HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J. Immunol. 142 (1989) 3091-3097
328. Westby M., Manca F., and Dalgleish A.G. The role of the immune responses in determining the outcome of HIV infection. Immunol. Today 17 (1996) 120-126
329. Westby M., Vaughan A.N., Balotta C., Galli M., Clerici M., and Dalgleish A.G. Low CD4 counts rather than superantigenic-like effects account for different expressed T-cell receptor (TCR) repertoires between HIV-1 seropositive long-term non-progressors and individuals with progressive disease. Br. J. Haematol. 102 (1998) 1187-1196
330. Westendrop M.O., Frank R., Ochsenbauer C., Stricker K., Dhein J., Waiczak H., Debatin K.M., and Krammer P.H. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375 (1995) 497-500
331. Weyland C.M., and Goronzy J.J. Mapping of allospecific T-cell recognition sites encoded by the HLA-DR4 β1-chain. Hum. Immunol. 24 (1989) 133-143
332. Weyland C.M., Hicok K.C., and Goronzy J.J. Non random selection of T cell specificities in anti-HLA-DR responses. Sequence motifs of the responder HLA-R allele influence T cell recruitment. J. Immunol. 147 (1991) 70-78
333. Whitaker R.E. Re-assessing the virological approach to HIV pathogenesis: Can it explain AIDS as an immunological disease?. J. Theor. Biol. 187 (1997) 45-56
334. Whitelegg A., and Barber L.D. The structural basis of T-cell allorecognition. Tissue Antigens 63 (2004) 101-108
335. Whittle H., Morris J., Todd J., Corrah T., Sabally S., Bangali J., Ngom P.T., Rolfe M., and Wilkins A. HIV-2 patients survive longer than HIV-1 infected patients. AIDS 8 (1994) 1617-1620
336. Wilkins A., Ricard D., Todd J., Whittle H., Dias F., and Da Silva A.P. The epidemiology of HIV infection in a rural area of guinea-Bissau. AIDS 7 (1993) 1119-1122
337. Wilson S.E., Habeshaw J.A., Addawe M.A., Hounsell E.F., and Oxford J.S. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogenous proliferative T cell responses to soluble antigens. AIDS Res. Hum. Retroviruses 13 (1997) 1313-1324
338. Wong M.T., Warren R.Q., Anderson S.A., Dolan M.J., Hendrix C.W., Blatt S.P., Melcher G.P., Boswell N., and Kennedy R.C. Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and non-progressing HIV-1-infected subjects. J. Infect. Dis. 168 (1993) 1523-1527
339. Young J.A.T. HIV and HLA similarity. Nature 333 (1988) 215
340. Yue F.Y., Kovacs C.M., Dimayuga R.C., Gu X.X.J., Parks P., Kaul R., and Ostrowski M.A. Preferential apoptosis of HIV-1-specific CD4+ T cells. J. Immunol. 174 (2005) 2196-2204
341. Yusim K., Kesmir C., Gaschen Addo M.M., Altfeld M., Brunak S., Chigaev A., Detours V., and Korber B.T. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J. Virol. 76 (2002) 8757-8768
342. Zagury J.F., Bernard J., Achour A., Astgen A., Lachgar A., Fall L., Carelli C., Issing W., Mbika J.P., Picard O., Carlotti M., Callebaut I., et al. Identification of CD4 and major histocompatiility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: Role in AIDS pathogenesis. Proc. Natl. Acad. Sci. USA 90 (1993) 7573-7577
343. Zaitseva M.B., Moshnikov S.A., Kozhich A.T., Frolova H.A., Makarova O.D., Pavlikov S.P., Sodorovich I.G., and Brondz B.B. Antibodies to MHC class II peptides are present in HIV-1 positive sera. Scand. J. Immunol. 35 (1992) 267-273
344. Zarling J.M., Ledbetter J.A., Sias J., Fultz P., Eichberg J., Gjerset G., and Moran P.A. HIV-infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells. J. Immunol. 144 (1990) 2992-2998
345. Zolla-Pazner P., O'Leary J., Burda S., Gorny M.K., Kim M., Mascola J., and McCutchan F. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J. Virol. 69 (1995) 3807-3815